I agree. As an investment at my average price/ share this is a terrible one. As a speculative investment only time will tell. Having been on board for only 4 years my heart goes out to those who have been invested since the IPO. Those who look for quick returns in biotech stocks are probably shorting.

It has always been my contention that all longs need to do is have an approved Afrezza before this stock gets very interesting. Of course the purveyors of FUD will simply change their tune to: "they fell short of expectations....they only added 400,000 new patients this quarter".